Published in Heart Fail Rev on June 01, 2006
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J (2015) 1.46
Office management of patients with diastolic heart failure. CMAJ (2009) 0.88
Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail (2013) 0.87
Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients. World J Cardiol (2010) 0.80
Diastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesia. J Saudi Heart Assoc (2012) 0.79
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". World J Cardiol (2015) 0.76
Heart failure. BMJ Clin Evid (2010) 0.75
Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review. Br J Clin Pharmacol (2011) 0.75
Heart failure. BMJ Clin Evid (2011) 0.75
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation (2000) 4.63
Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation (1998) 4.63
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol (1995) 3.19
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
Diagnosing heart failure. Eur Heart J (1999) 1.50
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol (1990) 1.34
Diastolic heart failure--no time to relax. N Engl J Med (2001) 1.20
Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation (1984) 1.20
Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group. Lancet (1988) 1.17
Diagnosing primary diastolic heart failure. Eur Heart J (2000) 0.96
Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis (1998) 0.89
Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol (1993) 0.89
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail (2005) 0.88
Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract (2002) 0.81
Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure. J Lab Clin Med (1989) 0.75
Diastolic dysfunction and heart failure: causes and treatment options. Cleve Clin J Med (2000) 0.75
Diagnosis and treatment of diastolic heart failure. Hosp Pract (1995) (1999) 0.75
How to treat diastolic heart failure: a personal point of view. Rev Port Cardiol (1999) 0.75
The treatment of diastolic heart failure. Cardiol Clin (2000) 0.75
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation (2010) 2.45
Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation (2008) 2.27
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J (2015) 1.68
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail (2010) 1.29
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J (2004) 1.25
Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation (2002) 1.21
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail (2008) 1.20
Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J (2013) 1.10
Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood (2011) 1.00
Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med (2012) 0.99
Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail (2013) 0.97
Effect of autophosphorylation on the catalytic and regulatory properties of protein tyrosine kinase Src. Arch Biochem Biophys (2002) 0.92
Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail (2006) 0.91
Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J (2012) 0.91
Targeting gelatinases with a near-infrared fluorescent cyclic His-Try-Gly-Phe peptide. Mol Imaging Biol (2009) 0.91
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm (2006) 0.90
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. Am Heart J (2010) 0.90
Determining the most appropriate components for a composite clinical trial outcome. Am Heart J (2008) 0.89
Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail (2009) 0.89
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail (2005) 0.88
Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail (2013) 0.86
Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis (2005) 0.85
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J (2005) 0.84
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. Am Heart J (2013) 0.84
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J (2004) 0.83
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg (2016) 0.82
Heart failure not enough pump iron? J Am Coll Cardiol (2011) 0.82
Contribution of an active site cation-pi interaction to the spectroscopic properties and catalytic function of protein tyrosine kinase Csk. Biochemistry (2002) 0.81
Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation (2002) 0.80
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail (2005) 0.80
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail (2007) 0.78
The statin wars. Lancet (2003) 0.78
The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci (2012) 0.78
Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study. Cardiovasc Drugs Ther (2004) 0.77
Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. Eur Heart J (2006) 0.77
Making sense of SENIORS. Eur Heart J (2005) 0.76
Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate. BMJ (2005) 0.76
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail (2015) 0.75
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail (2013) 0.75
CHF: a GP guide to management. Practitioner (2002) 0.75
Aldosterone blockade in post-acute myocardial infarction heart failure. Clin Cardiol (2006) 0.75
[Expert Consensus document on beta-adrenergic receptor blockers]. Rev Esp Cardiol (2005) 0.75
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease]. Rev Esp Cardiol (2004) 0.75